'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

Read more: LA fires: Why fast-moving wildfires and those started by human activities are more destructive and harder to contain Nights are warming faster than days globally, and dusk has brought ...

Moderna has lowered 2025 revenue guidance after a tough 2024 coronavirus vaccination season. However, the company aims to launch 10 new products over the next few years -- and that could lead to ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Ratings for Moderna MRNA were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings ...

Moderna's share price plunged after the company cut its 2025 sales guidance. The mRNA pioneer sees considerable uncertainty in the vaccine market. However, Moderna still expects 10 product ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

When I first saw that photo of Nvidia’s new Project Digits mini PC unveiled at CES 2025, I couldn’t help but notice the Apple influence — minimalist, sleek, next to a monitor that looks like ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...

The seventh-gen iPad Mini is now available in its full suite of colors starting at just $399. The seventh-gen iPad Mini is now available in its full suite of colors starting at just $399.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...